CTAG2
CTAG2 (Cancer/testis antigen 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma.
Overview
UniProt has no function text for O75638; HGNC names it "cancer/testis antigen 2".
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Letetresgene Autoleucel.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CTAG2 (Cancer/testis antigen 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma.
- 1 · What it is
CTAG2 (Cancer/testis antigen 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma.
- 2 · What goes wrong in cancer
UniProt has no function text for O75638; HGNC names it "cancer/testis antigen 2". Locus Xq28 (HGNC).
- 3 · How drugs use it
No product in this corpus aims at CTAG2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:2492 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O75638 (protein name, function text, keywords and locations (REST API)); CIViC gene CTAG2 (1 evidence items, 0 assertions, 1 variants; diseases: Multiple Myeloma (GraphQL API, CC0))
Biology
UniProt has no function text for O75638; HGNC names it "cancer/testis antigen 2". Locus Xq28 (HGNC).
- Multiple myeloma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CTAG2" OR ABSTRACT:"CTAG2" OR TITLE:"cancer/testis antigen 2" OR ABSTRACT:"cancer/testis antigen 2" OR TITLE:"Cancer/testis antigen 2" OR ABSTRACT:"Cancer/testis antigen 2" OR TITLE:"LAGE-1" OR ABSTRACT:"LAGE-1" OR TITLE:"CAMEL" OR ABSTRACT:"CAMEL" OR TITLE:"LAGE1" OR ABSTRACT:"LAGE1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CTAG2, not a curated reading list.